HPV

The HPV infection itself has no antiviral treatment: but about 90% of infections clear on their own as the immune system suppresses the virus, typically within 1–2 years. What clinicians can treat are the conditions HPV causes: genital warts (removed with topical medications or in-office procedures) and precancerous cervical changes (LEEP or cone biopsy). Treating precancerous lesions is highly effective and prevents cervical cancer from developing. Vaccination prevents future infections with covered types, it doesn't treat existing infections but does protect against types not yet acquired.

Gardasil 9 is routinely recommended at age 11–12 (starting as early as 9), with catch-up vaccination through age 26. Adults 27–45 may benefit through a shared clinical decision based on risk factors and prior exposure. The vaccine is most effective before any HPV exposure, but it is not pointless after sexual debut, it still protects against the nine covered types you haven't yet acquired. Studies show benefit even in people with prior HPV exposure. The vaccine is very safe with mild, brief side effects (sore arm, occasional low-grade fever). Given that HPV causes most cervical cancers and a growing fraction of oropharyngeal cancers, Gardasil 9 is one of the most effective cancer-prevention tools ever developed.

Persistent infection with high-risk HPV types, especially 16 and 18, disrupts normal cell-cycle regulation, causing precancerous changes (e.g., CIN 2/3 in the cervix) that can progress to invasive cancer over 10–20 years if undetected and untreated. This progression is slow enough that it can be interrupted at multiple points: (1) Gardasil 9 vaccination prevents the highest-risk types from ever establishing infection; (2) regular cervical screening detects precancerous changes when they are 100% treatable by LEEP or cone biopsy; (3) treating detected precancer prevents cancer from developing. The system works, countries with high vaccination and screening rates are seeing dramatic declines in cervical cancer incidence.

Genital warts appear as soft, flesh-colored, gray, or pink bumps, sometimes flat, sometimes raised, or cauliflower-shaped, on or around the genitals, anus, or groin. They are caused by low-risk HPV types 6 and 11, which are entirely separate from the high-risk cancer-causing types. Having genital warts does NOT mean you have a cancer-causing HPV type, though it is biologically possible to carry both simultaneously. Warts are diagnosed by visual examination on the same clinical visit; treatment options include topical prescription creams (imiquimod, podofilox) or in-office removal (cryotherapy, TCA, excision). Warts recur in 20–50% of cases because the virus persists in surrounding tissue.

HPV is so common, ~80% of sexually active people acquire it, that there is no clinical partner-notification protocol the way there is for chlamydia or syphilis. Because no test exists for men and most infections are transient, the calculus is different from bacterial STIs. That said, sharing what you know with a partner, especially if you have active warts or a recent abnormal cervical result, supports informed decision-making. The most actionable step for any partner is HPV vaccination. Partners with a cervix should also stay current on their cervical screening schedule.

For most pregnant people with HPV, the infection does not affect the pregnancy or the developing baby. Genital warts may grow faster during pregnancy due to hormonal and immune changes; imiquimod, podofilox, and sinecatechins are contraindicated: a clinician will advise on safe alternatives (TCA, cryotherapy, excision). Cervical precancer detected during pregnancy is typically managed conservatively, with definitive treatment deferred until after delivery unless invasive cancer is a concern. In rare cases, HPV types 6 and 11 can pass to a newborn during delivery and cause recurrent respiratory papillomatosis in the child's airway, another compelling reason for vaccination before pregnancy.

Yes. Clearing an infection with one HPV type provides no meaningful protection against the 200+ other HPV types, including other oncogenic types. Having been infected with HPV 16, for example, does not protect against HPV 18, 31, 33, or others. Gardasil 9 covers nine types, but sexual exposure can still involve types not covered by the vaccine. This is why vaccination before first sexual exposure (ideally covering as many types as possible before any exposure), combined with ongoing condom use and cervical screening, remains important even for people who have previously had HPV.

Yes. HPV, primarily type 16, now causes approximately 70% of oropharyngeal cancers (base of tongue, tonsils, posterior pharynx) in the United States, and this fraction has been rising for decades as tobacco-related cancers declined. HPV-related throat cancers are more common in men and often present at a more advanced stage because there is no routine screening test equivalent to the cervical Pap smear. Protection against HPV-related oropharyngeal cancer relies primarily on vaccination (Gardasil 9 covers HPV 16) and, to a lesser degree, using dental dams or condoms during oral sex, though these provide incomplete protection. There is currently no approved screening test or surveillance program for oropharyngeal HPV.

No, different HPV types cause warts at different body sites. Common hand warts and plantar warts (on the soles of the feet) are caused by low-risk non-genital HPV types (such as 1, 2, and 4), spread by non-sexual skin contact. The types that cause genital warts (HPV 6 and 11) and cancer-causing genital HPV types (16, 18, and others) are distinct from the ones responsible for hand and foot warts. Gardasil 9 does not protect against the HPV types that cause common hand or plantar warts. Over-the-counter wart removers designed for hand and foot warts, especially those with salicylic acid or freezing agents, are not safe for use on genital skin and should never be applied there.